Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedFeb 07, 2026
DataAggregated Company Financials
Companies40
  • 7D2.2%
  • 3M15.4%
  • 1Y21.2%
  • YTD2.4%

The Pharma industry is up 2.2% in the last week, with Astellas Pharma up 14%. This takes the industry's 12 month performance to a gain of 21%. Looking forward, earnings are forecast to grow by 8.2% annually.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 07 Feb 2026JP¥48.2tJP¥17.2tJP¥2.2t16.7x21.5x2.8x
Mon, 05 Jan 2026JP¥45.9tJP¥16.9tJP¥1.9t16.5x24.1x2.7x
Wed, 03 Dec 2025JP¥45.4tJP¥16.9tJP¥1.9t15.8x23.8x2.7x
Fri, 31 Oct 2025JP¥41.0tJP¥16.8tJP¥1.8t15.3x22.5x2.4x
Sun, 28 Sep 2025JP¥39.7tJP¥16.8tJP¥1.8t16.1x21.7x2.4x
Tue, 26 Aug 2025JP¥40.6tJP¥16.8tJP¥1.8t16.1x22.2x2.4x
Thu, 24 Jul 2025JP¥40.4tJP¥16.8tJP¥1.8t16.7x23.1x2.4x
Sat, 21 Jun 2025JP¥39.4tJP¥16.8tJP¥1.8t15.3x22.3x2.3x
Mon, 19 May 2025JP¥39.1tJP¥16.8tJP¥1.8t14.1x22.2x2.3x
Wed, 16 Apr 2025JP¥37.2tJP¥16.5tJP¥1.5t14.4x24.7x2.3x
Fri, 14 Mar 2025JP¥39.9tJP¥16.5tJP¥1.5t16.1x26.6x2.4x
Sun, 09 Feb 2025JP¥40.2tJP¥16.4tJP¥1.3t15.2x30.7x2.5x
Tue, 07 Jan 2025JP¥41.7tJP¥16.1tJP¥1.4t16.2x29.5x2.6x
Thu, 05 Dec 2024JP¥43.3tJP¥16.1tJP¥1.4t15.4x30.7x2.7x
Sat, 02 Nov 2024JP¥45.0tJP¥15.8tJP¥1.3t15.7x35.4x2.8x
Mon, 30 Sep 2024JP¥44.5tJP¥15.5tJP¥1.2t15.9x37.1x2.9x
Wed, 28 Aug 2024JP¥47.8tJP¥15.5tJP¥1.2t17.9x39.8x3.1x
Fri, 26 Jul 2024JP¥44.5tJP¥15.0tJP¥1.1t18.4x40.6x3x
Sun, 23 Jun 2024JP¥40.5tJP¥15.0tJP¥1.1t17.8x37x2.7x
Tue, 21 May 2024JP¥41.2tJP¥15.0tJP¥1.1t16.8x37.6x2.7x
Thu, 18 Apr 2024JP¥39.2tJP¥14.8tJP¥1.2t18.6x32.5x2.7x
Sat, 16 Mar 2024JP¥42.6tJP¥15.1tJP¥1.2t19.7x35.1x2.8x
Mon, 12 Feb 2024JP¥41.0tJP¥15.0tJP¥1.3t20.1x32x2.7x
Wed, 10 Jan 2024JP¥40.5tJP¥15.2tJP¥1.4t20x29.5x2.7x
Fri, 08 Dec 2023JP¥40.2tJP¥15.2tJP¥1.4t20.1x29.2x2.6x
Sun, 05 Nov 2023JP¥38.8tJP¥15.1tJP¥1.3t22.4x28.9x2.6x
Tue, 03 Oct 2023JP¥39.8tJP¥14.9tJP¥1.4t23.6x27.9x2.7x
Thu, 31 Aug 2023JP¥40.5tJP¥14.9tJP¥1.4t23.2x28.3x2.7x
Sat, 29 Jul 2023JP¥38.7tJP¥14.7tJP¥1.5t20.8x26.5x2.6x
Mon, 26 Jun 2023JP¥40.9tJP¥14.6tJP¥1.5t20.6x28x2.8x
Wed, 24 May 2023JP¥40.5tJP¥14.6tJP¥1.5t19.8x27.7x2.8x
Fri, 21 Apr 2023JP¥38.1tJP¥14.3tJP¥1.5t17.6x26x2.7x
Sun, 19 Mar 2023JP¥37.1tJP¥14.3tJP¥1.5t16.5x25.3x2.6x
Tue, 14 Feb 2023JP¥36.7tJP¥14.3tJP¥1.5t16.6x25.3x2.6x
Price to Earnings Ratio

25.3x


Total Market Cap: JP¥36.7tTotal Earnings: JP¥1.5tTotal Revenue: JP¥14.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.5x which is lower than its 3-year average PE of 28.7x.
  • The industry is trading close to its 3-year average PS ratio of 2.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 16% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market3.35%
Healthcare1.78%
Pharma2.16%
Pharma2.16%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4503 Astellas PharmaJP¥2.44k13.9%
+JP¥532.0b		70.3%PE13.5x
4502 Takeda PharmaceuticalJP¥5.52k5.2%
+JP¥434.4b		33.4%PE77.2x
4507 ShionogiJP¥3.39k6.9%
+JP¥186.4b		56.4%PE14.8x
4528 Ono PharmaceuticalJP¥2.48k7.9%
+JP¥85.5b		61.6%PE18.7x
4578 Otsuka HoldingsJP¥9.34k1.1%
+JP¥54.4b		17.9%PE11x

Latest News

4568
JP¥2,869.00
Daiichi Sankyo Company
7D
1.2%
1Y
-25.2%

There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings

Feb 06
There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings
4506
JP¥2,229.50
Sumitomo Pharma
7D
-2.9%
1Y
191.4%

Investors Shouldn't Be Too Comfortable With Sumitomo Pharma's (TSE:4506) Earnings

Feb 06
Investors Shouldn't Be Too Comfortable With Sumitomo Pharma's (TSE:4506) Earnings
4519
JP¥8,608.00
Chugai Pharmaceutical
7D
-2.2%
1Y
24.4%
4523
JP¥4,482.00
Eisai
7D
4.0%
1Y
-0.5%

4523: Future Margin Upside From Subcutaneous Alzheimer’s Treatment Will Support Higher Returns

Analysts have lifted their fair value estimate for Eisai to ¥6,200 from ¥6,000, citing updated assumptions that combine a slightly higher discount rate and lower revenue growth with a stronger projected profit margin and a lower future P/E multiple. What's in the News Eisai and BioArctic submitted a Marketing Authorisation Variation to the European Medicines Agency for once every four weeks IV maintenance dosing of lecanemab, following an initial once every two weeks regimen for 18 months in early Alzheimer’s disease.
4503
JP¥2,441.00
Astellas Pharma
7D
13.9%
1Y
70.3%

4503: Elevated Earnings Outlook Will Likely Mask Higher Long Term Margin Risks

Analysts have increased their fair value estimate for Astellas Pharma from ¥1,300 to ¥1,500, citing updated assumptions that include a revised revenue growth profile, higher projected profit margins, and a lower anticipated future P/E multiple. What's in the News Astellas raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, supported by XTANDI and mirabegron products and foreign exchange effects (Key Developments).
4528
JP¥2,484.50
Ono Pharmaceutical
7D
7.9%
1Y
61.6%

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 05
Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
4540
JP¥4,196.00
Tsumura
7D
2.8%
1Y
-3.0%
4502
JP¥5,517.00
Takeda Pharmaceutical
7D
5.2%
1Y
33.4%

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥100.00

Feb 03
Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥100.00
4886
JP¥2,400.00
ASKA Pharmaceutical HoldingsLtd
7D
-3.9%
1Y
24.9%
4507
JP¥3,393.00
Shionogi
7D
6.9%
1Y
56.4%
4547
JP¥4,530.00
Kissei Pharmaceutical
7D
-1.5%
1Y
22.1%

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥100.00

Feb 03
Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥100.00
4578
JP¥9,344.00
Otsuka Holdings
7D
1.1%
1Y
17.9%

4578: Future Repricing Will Rely On Improved Execution And Capital Returns

Narrative Update Analysts have lifted their price target for Otsuka Holdings from ¥11,000 to ¥12,600, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that were reflected in recent Street research, including the latest upgrade from Morgan Stanley. Analyst Commentary Bullish analysts are leaning into a more constructive view on Otsuka Holdings, pointing to updated assumptions on growth, profitability and valuation that support a higher price target range.
4536
JP¥1,719.00
Santen Pharmaceutical
7D
-1.1%
1Y
19.0%
4151
JP¥2,402.50
Kyowa Kirin
7D
-4.1%
1Y
13.5%
4887
JP¥2,362.50
Sawai Group Holdings
7D
-0.3%
1Y
24.5%

Sawai Group Holdings Co., Ltd. (TSE:4887) Stock Rockets 26% But Many Are Still Ignoring The Company

Dec 16
Sawai Group Holdings Co., Ltd. (TSE:4887) Stock Rockets 26% But Many Are Still Ignoring The Company
4516
JP¥5,042.00
Nippon Shinyaku
7D
-2.2%
1Y
29.4%

Nippon Shinyaku (TSE:4516) Has Affirmed Its Dividend Of ¥62.00

Dec 06
Nippon Shinyaku (TSE:4516) Has Affirmed Its Dividend Of ¥62.00